A Phase 1a/b Clinical Trial To Determine the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Efficacy of BB-TL1A-VIAL-HLE in Healthy Adult Volunteers and in Patients With Moderate-To-Severe Ulcerative Colitis
Latest Information Update: 27 Jun 2025
At a glance
- Drugs VIAL TL1A HLE (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Battery Bio Australia
Most Recent Events
- 27 Jun 2025 New trial record
- 25 Jun 2025 According to a VIAL media release, the company has successfully dosed first participant in this trial. Interim subcutaneous safety and pharmacokinetic data from healthy volunteers are expected in H2 2025.